Evaluating the Use of a Concentrated Surfactant Gel in Burn Patients

Burns Clinical Trial

Official title:

Evaluating the Use of a Concentrated Surfactant Gel in Burn Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04084093
• Other study ID #: MED-2018-DIV31-011
• Status: Withdrawn
• Phase: N/A
• Start date: February 12, 2020
• Est. completion date: April 8, 2020

Study information

• Verified date: September 2019
• Source: Medline Industries
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be an observational study evaluating subject's perception of pain to dressing changes during removal and application of a surfactant gel. Wound healing will also be monitored. Anxiety before dressing change will be measured using a burn specific pain anxiety scale. Study intervention will include cleansing the wound per the facility's standard of care, followed by applying the investigational product on the wound. This will be followed by placing an appropriate secondary dressing.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 8, 2020
• Est. primary completion date: April 8, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject should be an inpatient, per the Two-Midnight rule at the time of study initiation.

• At the time of subject's admission in the hospital, duration of his or her burn wound should be < or equal to 24 hours.

• Subject who has a partial thickness burn wound, or an indeterminate burn wound, or who has both these characteristics in the same wound, as determined by the site Principal Investigator.

• Subject's wound included in this study, does not require any surgical intervention.

• Subject is able and willing to comply with requirements of this trial protocol.

• Voluntarily signed informed consent obtained before any trial-related procedures are performed.

• Subject must be able to communicate effectively with study personnel.

• Subject has burn total body surface area (TBSA) between 1-20%.

Exclusion Criteria:

• Subjects with electrical or radiation burns.

• Subjects who are pregnant, nursing or planning to become pregnant during the course of the study.

• Subjects who have known allergies to any ingredients in the dressings used in the study.

• Subjects taking opiates during the study duration.

• Subjects with an active diagnosis of substance use disorder within the past six months.

• Subjects with previously diagnosed issues with pain perception, including conditions such as peripheral neuropathy, if they will preclude accurate assessment of primary and secondary endpoints.

• Subjects with an active infection prior to enrollment.

• Subject has previous or current systemic disease(s) which, in the judgement of the investigator, is likely to interfere with treatment. Subjects with well-controlled diabetes mellitus (HbA1C<8.5) shall be permitted.

Related Conditions & MeSH terms

• Burns

Intervention

Device:
• Surfactant Gel
This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.

Locations

Country	Name	City	State
United States	Baton Rouge General Medical Center	Baton Rouge	Louisiana
United States	Loyola University Medical Center	Maywood	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Medline Industries

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Self-reported evaluation of subject pain perception during dressing changes using a numerical pain scale.	The numerical pain scale will be from 0 to 10 with 0 being no pain at all and 10 being the worst pain ever possible. This is the numeric rating scale.	Baseline to Day 30
Secondary	Measure percent change in epithelium as recorded by the clinician.		Baseline to Day 30
Secondary	Measure percent change in necrotic tissue in the wound bed		Baseline to Day 30
Secondary	Measure change in wound size		Baseline to Day 30
Secondary	Measure anxiety using a burn specific anxiety scale	A burn-specific pain anxiety scale will be used to measure level of anxiety. Items will be scored on a 100mm visual analog line with two reference points, 0 and 100. These reference points will also be identified by expressions "not at all" and "the worst imaginable way". Subjects will be requested to scale the strength of their feelings relative to two reference points.	Baseline to Day 30